Cargando…

Osteonectin as a screening marker for pancreatic cancer: A prospective study

OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Papapanagiotou, Angeliki, Sgourakis, George, Karkoulias, Kyriakos, Raptis, Dimitris, Parkin, Edward, Brotzakis, Pantelis, Panchal, Sanjay, Papavassiliou, Athanasios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124255/
https://www.ncbi.nlm.nih.gov/pubmed/29756486
http://dx.doi.org/10.1177/0300060518772413
_version_ 1783353004009717760
author Papapanagiotou, Angeliki
Sgourakis, George
Karkoulias, Kyriakos
Raptis, Dimitris
Parkin, Edward
Brotzakis, Pantelis
Panchal, Sanjay
Papavassiliou, Athanasios G.
author_facet Papapanagiotou, Angeliki
Sgourakis, George
Karkoulias, Kyriakos
Raptis, Dimitris
Parkin, Edward
Brotzakis, Pantelis
Panchal, Sanjay
Papavassiliou, Athanasios G.
author_sort Papapanagiotou, Angeliki
collection PubMed
description OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls. RESULTS: The median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups. CONCLUSION: Osteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies.
format Online
Article
Text
id pubmed-6124255
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61242552018-09-10 Osteonectin as a screening marker for pancreatic cancer: A prospective study Papapanagiotou, Angeliki Sgourakis, George Karkoulias, Kyriakos Raptis, Dimitris Parkin, Edward Brotzakis, Pantelis Panchal, Sanjay Papavassiliou, Athanasios G. J Int Med Res Clinical Research Reports OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls. RESULTS: The median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups. CONCLUSION: Osteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies. SAGE Publications 2018-05-13 2018-07 /pmc/articles/PMC6124255/ /pubmed/29756486 http://dx.doi.org/10.1177/0300060518772413 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Clinical Research Reports
Papapanagiotou, Angeliki
Sgourakis, George
Karkoulias, Kyriakos
Raptis, Dimitris
Parkin, Edward
Brotzakis, Pantelis
Panchal, Sanjay
Papavassiliou, Athanasios G.
Osteonectin as a screening marker for pancreatic cancer: A prospective study
title Osteonectin as a screening marker for pancreatic cancer: A prospective study
title_full Osteonectin as a screening marker for pancreatic cancer: A prospective study
title_fullStr Osteonectin as a screening marker for pancreatic cancer: A prospective study
title_full_unstemmed Osteonectin as a screening marker for pancreatic cancer: A prospective study
title_short Osteonectin as a screening marker for pancreatic cancer: A prospective study
title_sort osteonectin as a screening marker for pancreatic cancer: a prospective study
topic Clinical Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124255/
https://www.ncbi.nlm.nih.gov/pubmed/29756486
http://dx.doi.org/10.1177/0300060518772413
work_keys_str_mv AT papapanagiotouangeliki osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT sgourakisgeorge osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT karkouliaskyriakos osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT raptisdimitris osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT parkinedward osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT brotzakispantelis osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT panchalsanjay osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy
AT papavassiliouathanasiosg osteonectinasascreeningmarkerforpancreaticcanceraprospectivestudy